Toxicology, Epidemiology Join to Explore Cancer Hazards

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 4
Volume 8
Issue 4

ANAHEIM, Calif-Although toxicology and epidemiology have both contributed importantly to our understanding of cancer hazards, researchers have now “gone as far as we can go” using each discipline separately, Christopher Schonwalder, PhD, said at a symposium on mixed environmental hazards and cancer at the annual meeting of the American Association for the Advancement of Science (AAAS).

ANAHEIM, Calif—Although toxicology and epidemiology have both contributed importantly to our understanding of cancer hazards, researchers have now “gone as far as we can go” using each discipline separately, Christopher Schonwalder, PhD, said at a symposium on mixed environmental hazards and cancer at the annual meeting of the American Association for the Advancement of Science (AAAS).

Dr. Schonwalder, director of the Office of International Programs at the National Institute of Environmental Health Science’s Office of Hazard Assessment, Research Triangle Park, North Carolina, said that each of these disciplines has been useful, but that further progress now demands that researchers bring them together.

Billions Spent on Compliance

The nation now spends $150 to $400 billion each year on compliance with environmental laws, Dr. Schonwalder said, but “we know we’re not getting it right.” Current policies overcontrol some hazards, accruing unnecessary costs, but undercontrol others, permitting needless disease.

Congress expects science to determine what is safe, he said, and the law requires action based on scientific findings. Existing scientific knowledge, however, does not allow a more precise or accurate application of environmental controls.

“‘Safe’ is subjective,” he said, and important public policy decisions now must be made on the basis of limited information. “In the absence of better knowledge,” he said, “policy makers are forced to use defaults or to apply the precautionary principle, which can result in tremendous overcontrol of certain factors, while some important hazards are undoubtedly currently undercontrolled.”

Better Information Required

With one-third of cancers now attributed to known environmental factors, one-third considered environmentally related, and one-third attributed to genetics or unknown factors, sound public health policy will require better information, Dr. Schonwalder said. Both data and understanding are needed to reach the right balance, and that will require a more comprehensive approach to the study of hazards than has been used in the past, he said.

The public health approach to hazards emphasizes prevention in populations and depends on measures of effectiveness, which are difficult to devise for cancer, he said. Public health approaches to existing problems seek to identify the greatest risks and to discern problems and solutions in context.

Potential problems, on the other hand, such as chemicals newly introduced into the environment, require a bottom-up approach to hazard analysis, beginning with toxicology, proceeding to an understanding of the cause and effect of disease processes, and culminating in a determination of whether the new exposure will lead to health problems in the future.

This approach, he noted, allows better predictions. Twenty years ago, toxicologists knew very little about the mechanisms that turn exposure into disease. But, more recently, considerable progress has been made in understanding a number of specific hazards.

Role of Epidemiology

Epidemiology provides different but important elements of the hazard equation, Dr. Schonwalder said. An observational science, it identifies risk factors by studying the occurrence of diseases in populations, as opposed to toxicology, a lab science that measures dose-response interactions within individuals.

Although useful in isolating potential hazards, epidemiology is not sufficient to understand the hazard-disease relationship, he said, because it often provides relatively weak associations and conflicting results, while being sensitive to large confounders. Exposure assessment, which is often technically difficult or impossible to do accurately, forms a very weak link in many epidemiologic studies.

The use of biomarkers in epidemiologic studies, he suggested, could solve this problem.

Recent Videos
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content